{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T01:02:51Z","timestamp":1784509371028,"version":"3.55.0"},"reference-count":243,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Peroxisome proliferator-activated receptors (PPAR\u03b1, PPAR\u03b2\/\u03b4, and PPAR\u03b3) are ligand-activated nuclear transcription factors that orchestrate key metabolic and immuno-inflammatory networks governing hepatic homeostasis. By regulating fatty acid oxidation, insulin signaling, bile acid metabolism, and hepatic stellate cell activation, PPARs integrate metabolic and inflammatory cues central to the pathogenesis of chronic liver disorders. Chronic liver diseases (CLDs) constitute a major and growing global health burden. Metabolic dysfunction-associated steatotic liver disease (MASLD), now affecting up to one-third of the adult population worldwide, is closely linked to type 2 diabetes, cardiovascular disease, and major liver-related events. In parallel, chronic immune-mediated cholestatic liver diseases continue to pose important therapeutic challenges. Although ursodeoxycholic acid remains the standard first-line therapy for primary biliary cholangitis (PBC), and several second-line therapeutic options are now available, a substantial proportion of patients exhibit an incomplete biochemical response, while effective disease-modifying therapies for primary sclerosing cholangitis (PSC) remain lacking. Across etiologies, persistent metabolic stress, immune-mediated injury, and maladaptive fibrogenesis represent convergent pathogenic pathways. In MASLD, PPAR agonists have shown promising effects on steatosis, necroinflammatory activity, and fibrosis regression in randomized clinical trials, positioning them among the most advanced pharmacological strategies currently under investigation. In cholestatic liver diseases, selective and dual PPAR agonists have demonstrated significant improvements in cholestasis, pruritus, and markers of disease activity, supporting their role as second-line or adjunctive therapy. This review critically appraises the current preclinical and clinical evidence on the role of PPARs in CLDs, delineates the underlying molecular mechanisms, and discusses future therapeutic perspectives. Although the available evidence is encouraging, most clinical studies have primarily demonstrated improvements in surrogate biochemical and histological endpoints rather than hard clinical outcomes. Ongoing phase III trials and long-term outcome studies will be essential to define the role of PPAR agonists within future therapeutic algorithms for CLDs.<\/jats:p>","DOI":"10.3390\/cells15141292","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:47:32Z","timestamp":1784508452000},"page":"1292","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-9019","authenticated-orcid":false,"given":"Mario","family":"Romeo","sequence":"first","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5473-3440","authenticated-orcid":false,"given":"Claudio","family":"Basile","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Imperatore","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giambattista","family":"Mozzi","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiammetta","family":"Di Nardo","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2392-3539","authenticated-orcid":false,"given":"Carmine","family":"Napolitano","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vaia","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9705-0037","authenticated-orcid":false,"given":"Luigi","family":"Di Puorto","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4150-4722","authenticated-orcid":false,"given":"Mattia","family":"Indipendente","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4153-815X","authenticated-orcid":false,"given":"Marcello","family":"Dallio","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-0793","authenticated-orcid":false,"given":"Alessandro","family":"Federico","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e70058","DOI":"10.1111\/liv.70058","article-title":"Global Burden of Major Chronic Liver Diseases in 2021","volume":"45","author":"Feng","year":"2025","journal-title":"Liver Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cld.1061","article-title":"Global Epidemiology of Chronic Liver Disease","volume":"17","author":"Cheemerla","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of Non-Alcoholic and Alcoholic Fatty Liver Diseases","volume":"5","author":"Mitra","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rojas-Amaris, N., Marenco-Flores, A., Lara-Romero, C., Barba, R., Rubio-Cruz, D., Parraga, X., Goyes, D., Medina-Morales, J.E., Sierra, L., and Romero-Gomez, M. (2025). Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Fatigue and Pruritus in Primary Sclerosing Cholangitis: A U.S. Single-Center Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14228083"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e70511","DOI":"10.1111\/liv.70511","article-title":"Progression to Decompensation of Severe Fibrosis Compared to Cirrhosis in MASLD: A Systematic Review and Meta-Analysis","volume":"46","author":"Barrett","year":"2026","journal-title":"Liver Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.32074\/1591-951X-245","article-title":"Autoimmune Biliary Diseases: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1053\/j.gastro.2025.03.010","article-title":"Regulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction-Associated Steatohepatitis","volume":"169","author":"Kisseleva","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3748\/wjg.v26.i17.1993","article-title":"Metabolic Inflammation as an Instigator of Fibrosis during Non-Alcoholic Fatty Liver Disease","volume":"26","author":"Katsarou","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3892\/ijmm.2025.5668","article-title":"Metabolic Dysfunction-associated Steatotic Liver Disease: Pathogenesis, Model and Treatment (Review)","volume":"56","author":"Ma","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrm3904","article-title":"Remodelling the Extracellular Matrix in Development and Disease","volume":"15","author":"Bonnans","year":"2014","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.14218\/JCTH.2020.00026","article-title":"Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?","volume":"8","author":"Chang","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhao, L., Tang, H., and Cheng, Z. (2024). Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances. Pharmaceuticals, 17.","DOI":"10.3390\/ph17121724"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"154338","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The Role of Peroxisome Proliferator-Activated Receptors (PPAR) in Immune Responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wagner, N., and Wagner, K.-D. (2020). The Role of PPARs in Disease. Cells, 9.","DOI":"10.3390\/cells9112367"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The Mechanisms of Action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jare.2023.08.006","article-title":"Forsythiaside A Alleviates Acute Lung Injury by Inhibiting Inflammation and Epithelial Barrier Damages in Lung and Colon through PPAR-\u03b3\/RXR-\u03b1 Complex","volume":"60","author":"Wang","year":"2024","journal-title":"J. Adv. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e00107-17","DOI":"10.1128\/MCB.00107-17","article-title":"Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor \u03b3-Retinoid X Receptor \u03b1 Coactivator","volume":"38","author":"Liersemann","year":"2018","journal-title":"Mol. Cell. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New Treatment Paradigms in Primary Biliary Cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_21","first-page":"145","article-title":"Prevention\/Reversal of Choline Deficiency-Induced Steatohepatitis by a Peroxisome Proliferator-Activated Receptor Alpha Ligand in Rats","volume":"16","author":"Rao","year":"2002","journal-title":"In Vivo"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2002-06-1762","article-title":"Fibrates Down-Regulate IL-1-Stimulated C-Reactive Protein Gene Expression in Hepatocytes by Reducing Nuclear P50-NFkappa B-C\/EBP-Beta Complex Formation","volume":"101","author":"Kleemann","year":"2003","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13919","DOI":"10.1073\/pnas.241410198","article-title":"Structural Determinants of Ligand Binding Selectivity between the Peroxisome Proliferator-Activated Receptors","volume":"98","author":"Xu","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/415813a","article-title":"Structural Basis for Antagonist-Mediated Recruitment of Nuclear Co-Repressors by PPARalpha","volume":"415","author":"Xu","year":"2002","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1073\/pnas.96.4.1585","article-title":"Mouse Steroid Receptor Coactivator-1 Is Not Essential for Peroxisome Proliferator-Activated Receptor Alpha-Regulated Gene Expression","volume":"96","author":"Qi","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cmet.2005.04.002","article-title":"\u201cNew\u201d Hepatic Fat Activates PPARalpha to Maintain Glucose, Lipid, and Cholesterol Homeostasis","volume":"1","author":"Chakravarthy","year":"2005","journal-title":"Cell Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"27307","DOI":"10.1074\/jbc.272.43.27307","article-title":"Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-Activated Receptor Alpha-Deficient Mice","volume":"272","author":"Peters","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI117717","article-title":"Fibrates Downregulate Apolipoprotein C-III Expression Independent of Induction of Peroxisomal Acyl Coenzyme A Oxidase. A Potential Mechanism for the Hypolipidemic Action of Fibrates","volume":"95","author":"Staels","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_29","first-page":"893","article-title":"Quercetin Protects against Atherosclerosis by Regulating the Expression of PCSK9, CD36, PPAR\u03b3, LXR\u03b1 and ABCA1","volume":"44","author":"Jia","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1111\/jcmm.18000","article-title":"Oridonin Attenuates Atherosclerosis by Inhibiting Foam Macrophage Formation and Inflammation through FABP4\/PPAR\u03b3 Signalling","volume":"27","author":"Zhang","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.tcb.2020.02.007","article-title":"Cholesterol Handling in Lysosomes and Beyond","volume":"30","author":"Meng","year":"2020","journal-title":"Trends Cell Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI11497","article-title":"PPARalpha Deficiency Reduces Insulin Resistance and Atherosclerosis in apoE-Null Mice","volume":"107","author":"Tordjman","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI118271","article-title":"Macrophage-Specific Expression of Human Apolipoprotein E Reduces Atherosclerosis in Hypercholesterolemic Apolipoprotein E-Null Mice","volume":"96","author":"Bellosta","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/toxsci\/kfaf049","article-title":"Comparison of Phenotypic and Transcriptomic Profiles between HFPO-DA and Prototypical PPAR\u03b1, PPAR\u03b3, and Cytotoxic Agents in Wild-Type and Ppara-Null Mouse Livers","volume":"206","author":"Heintz","year":"2025","journal-title":"Toxicol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/toxsci\/kfab068","article-title":"Species Differences between Mouse and Human PPAR\u03b1 in Modulating the Hepatocarcinogenic Effects of Perinatal Exposure to a High-Affinity Human PPAR\u03b1 Agonist in Mice","volume":"183","author":"Foreman","year":"2021","journal-title":"Toxicol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Shizu, R., Ezaki, K., Sato, T., Sugawara, A., Hosaka, T., Sasaki, T., and Yoshinari, K. (2021). PXR Suppresses PPAR\u03b1-Dependent HMGCS2 Gene Transcription by Inhibiting the Interaction between PPAR\u03b1 and PGC1\u03b1. Cells, 10.","DOI":"10.3390\/cells10123550"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101291","DOI":"10.1016\/j.molmet.2021.101291","article-title":"Pioneer Factor Foxa2 Enables Ligand-Dependent Activation of Type II Nuclear Receptors FXR and LXR\u03b1","volume":"53","author":"Kain","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"Glynn","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hida, Y., Imamura, T., and Kinugawa, K. (2023). Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia. J. Clin. Med., 12.","DOI":"10.3390\/jcm12216915"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tem.2023.10.002","article-title":"Mechanisms of Hepatic Fatty Acid Oxidation and Ketogenesis during Fasting","volume":"35","author":"Ruppert","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/1873-3468.12742","article-title":"From Chronic Overnutrition to Metaflammation and Insulin Resistance: Adipose Tissue and Liver Contributions","volume":"591","author":"Caputo","year":"2017","journal-title":"FEBS Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1002\/hed.26286","article-title":"Effects of PPAR-\u03b3 Agonists on Oral Cancer Cell Lines: Potential Horizons for Chemopreventives and Adjunctive Therapies","volume":"42","author":"Hall","year":"2020","journal-title":"Head Neck"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/shk.0b013e31804f56b9","article-title":"Diverse Cardioprotective Signaling Mechanisms of Peroxisome Proliferator-Activated Receptor-Gamma Ligands, 15-Deoxy-Delta12,14-Prostaglandin J2 and Ciglitazone, in Reperfusion Injury: Role of Nuclear Factor-kappaB, Heat Shock Factor 1, and Akt","volume":"28","author":"Zingarelli","year":"2007","journal-title":"Shock"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hamblin, M.H., Boese, A.C., Murad, R., and Lee, J.-P. (2025). PPAR\u03b1 Genetic Deletion Reveals Global Transcriptional Changes in the Brain and Exacerbates Cerebral Infarction in a Mouse Model of Stroke. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094082"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jhep.2025.06.021","article-title":"Somatic Loss-of-Function Mutations in CIDEB Reduce Hepatic Steatosis by Increasing Lipolysis and Fatty Acid Oxidation","volume":"84","author":"Zeng","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.cmet.2024.04.015","article-title":"A 5:2 Intermittent Fasting Regimen Ameliorates NASH and Fibrosis and Blunts HCC Development via Hepatic PPAR\u03b1 and PCK1","volume":"36","author":"Gallage","year":"2024","journal-title":"Cell Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2412473122","DOI":"10.1073\/pnas.2412473122","article-title":"Transferrin Promotes Fatty Acid Oxidation and Liver Tumor Growth through PHD2-Mediated PPAR\u03b1 Hydroxylation in an Iron-Dependent Manner","volume":"122","author":"Qian","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00041433-199904000-00009","article-title":"Peroxisome Proliferator-Activated Receptor Alpha in Metabolic Disease, Inflammation, Atherosclerosis and Aging","volume":"10","author":"Gervois","year":"1999","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1161\/ATVBAHA.112.247890","article-title":"Lipid Effects of Peroxisome Proliferator-Activated Receptor-\u03b4 Agonist GW501516 in Subjects with Low High-Density Lipoprotein Cholesterol: Characteristics of Metabolic Syndrome","volume":"32","author":"Olson","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.1038\/s41467-021-27428-9","article-title":"Oxidative Stress-Induced FABP5 S-Glutathionylation Protects against Acute Lung Injury by Suppressing Inflammation in Macrophages","volume":"12","author":"Guo","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/1874467210902010046","article-title":"Peroxisome Proliferator-Activated Receptor (PPAR) Beta\/Delta: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome","volume":"2","author":"Coll","year":"2009","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biochi.2016.12.008","article-title":"PPAR\u03b2 in Macrophages and Atherosclerosis","volume":"136","author":"Staels","year":"2017","journal-title":"Biochimie"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pharmthera.2009.12.001","article-title":"Peroxisome Proliferator-Activated Receptor Beta\/Delta (PPARbeta\/Delta) Acts as Regulator of Metabolism Linked to Multiple Cellular Functions","volume":"125","author":"Wagner","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bbadis.2017.01.004","article-title":"The Effects of PPAR\u03b3 on the Regulation of the TOMM40-APOE-C1 Genes Cluster","volume":"1863","author":"Subramanian","year":"2017","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1093\/nar\/gks025","article-title":"Dataset Integration Identifies Transcriptional Regulation of microRNA Genes by PPAR\u03b3 in Differentiating Mouse 3T3-L1 Adipocytes","volume":"40","author":"John","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"23975","DOI":"10.1074\/jbc.270.41.23975","article-title":"Differential Activation of Peroxisome Proliferator-Activated Receptors by Eicosanoids","volume":"270","author":"Yu","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tips.2004.03.012","article-title":"Peroxisome Proliferator-Activated Receptor Gamma in Diabetes and Metabolism","volume":"25","author":"Rangwala","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/386407a0","article-title":"Sensitization of Diabetic and Obese Mice to Insulin by Retinoid X Receptor Agonists","volume":"386","author":"Mukherjee","year":"1997","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/79216","article-title":"The Common PPARgamma Pro12Ala Polymorphism Is Associated with Decreased Risk of Type 2 Diabetes","volume":"26","author":"Altshuler","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"115928","DOI":"10.1016\/j.bcp.2023.115928","article-title":"Berberine Protects Mice against Type 2 Diabetes by Promoting PPAR\u03b3-FGF21-GLUT2-Regulated Insulin Sensitivity and Glucose\/Lipid Homeostasis","volume":"218","author":"Chen","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1097-2765(00)80210-5","article-title":"PPAR Gamma Mediates High-Fat Diet-Induced Adipocyte Hypertrophy and Insulin Resistance","volume":"4","author":"Kubota","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.7150\/thno.22565","article-title":"Adipocyte-Derived Exosomal MiR-27a Induces Insulin Resistance in Skeletal Muscle Through Repression of PPAR\u03b3","volume":"8","author":"Yu","year":"2018","journal-title":"Theranostics"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/hep4.1680","article-title":"Relationship of ELF and PIIINP with Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial","volume":"5","author":"Gawrieh","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12951-025-03900-2","article-title":"NUP85 siRNA Loaded Red Blood Cell-Derived Extracellular Vesicles Alleviate Hepatic Steatosis in MASLD","volume":"24","author":"Zhang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: The Diverse Biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-pathol-011110-130138","article-title":"Alternative Macrophage Activation and Metabolism","volume":"6","author":"Odegaard","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature05894","article-title":"Macrophage-Specific PPARgamma Controls Alternative Activation and Improves Insulin Resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00403-009-0959-1","article-title":"Activation of Peroxisome Proliferator-Activated Receptor-Gamma Inhibits Transforming Growth Factor-Beta1 Induction of Connective Tissue Growth Factor and Extracellular Matrix in Hypertrophic Scar Fibroblasts in Vitro","volume":"301","author":"Zhang","year":"2009","journal-title":"Arch. Dermatol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"117909","DOI":"10.1016\/j.lfs.2020.117909","article-title":"Activation of Nrf2\/AREs-Mediated Antioxidant Signalling, and Suppression of Profibrotic TGF-\u03b21\/Smad3 Pathway: A Promising Therapeutic Strategy for Hepatic Fibrosis-A Review","volume":"256","author":"Gong","year":"2020","journal-title":"Life Sci."},{"key":"ref_70","unstructured":"European Association for the Study of the Liver (EASL) (2024). European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","article-title":"Lipid Metabolism in MASLD and MASH: From Mechanism to the Clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"156128","DOI":"10.1016\/j.metabol.2024.156128","article-title":"PPAR\u03b1-ERR\u03b1 Crosstalk Mitigates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression","volume":"164","author":"Antwi","year":"2025","journal-title":"Metabolism"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1210\/en.2005-1132","article-title":"Peroxisome Proliferator-Activated Receptor Alpha Mediates the Effects of High-Fat Diet on Hepatic Gene Expression","volume":"147","author":"Patsouris","year":"2006","journal-title":"Endocrinology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.33160\/yam.2025.05.002","article-title":"Selective PPAR\u03b1 Modulator (SPPARM\u03b1) in the Era of the MASLD Pandemic: Current Insights and Future Prospects","volume":"68","author":"Sugihara","year":"2025","journal-title":"Yonago Acta Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e2415846","DOI":"10.1002\/advs.202415846","article-title":"Asprosin-FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPAR\u03b1 Contributing to MASLD Development","volume":"12","author":"Yu","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Dallio, M., Sangineto, M., Romeo, M., Villani, R., Romano, A.D., Loguercio, C., Serviddio, G., and Federico, A. (2021). Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010436"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Palma, R., Pronio, A., Romeo, M., Scognamiglio, F., Ventriglia, L., Ormando, V.M., Lamazza, A., Pontone, S., Federico, A., and Dallio, M. (2022). The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133649"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI200317223","article-title":"Liver-Specific Disruption of PPARgamma in Leptin-Deficient Mice Improves Fatty Liver but Aggravates Diabetic Phenotypes","volume":"111","author":"Matsusue","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1096\/fj.10-173716","article-title":"Role for PPAR\u03b3 in Obesity-Induced Hepatic Steatosis as Determined by Hepatocyte- and Macrophage-Specific Conditional Knockouts","volume":"25","author":"Titos","year":"2011","journal-title":"FASEB J."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhang, Y., and Wang, Y. (2025). Overexpression of Apolipoprotein A-I Alleviates Insulin Resistance in MASLD Mice Through the PPAR\u03b1 Pathway. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031051"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune Mechanisms Linking Metabolic Injury to Inflammation and Fibrosis in Fatty Liver Disease-Novel Insights into Cellular Communication Circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Carrera, M., and Wahli, W. (2022). PPARs as Key Mediators in the Regulation of Metabolism and Inflammation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095025"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1042\/CS20257571","article-title":"The Physiology of MASLD: Molecular Pathways between Liver and Adipose Tissues","volume":"139","author":"Lee","year":"2025","journal-title":"Clin. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"99312","DOI":"10.3748\/wjg.v31.i4.99312","article-title":"Elafibranor, a Dual PPAR\u03b1 and PPAR\u03b4 Agonist, Reduces Alcohol-Associated Liver Disease: Lessons from a Mouse Model","volume":"31","author":"Pirola","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ye, X., Zhang, T., and Han, H. (2022). PPAR\u03b1: A Potential Therapeutic Target of Cholestasis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.916866"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1042\/CS20220674","article-title":"Potential Therapeutic Action of Tauroursodeoxycholic Acid against Cholestatic Liver Injury via Hepatic Fxr\/Nrf2 and CHOP-DR5-Caspase-8 Pathway","volume":"137","author":"Song","year":"2023","journal-title":"Clin. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Cindoruk, M., Kerem, M., Karakan, T., Salman, B., Akin, O., Alper, M., Erdem, O., and Unal, S. (2007). Peroxisome Proliferators-Activated Alpha Agonist Treatment Ameliorates Hepatic Damage in Rats with Obstructive Jaundice: An Experimental Study. BMC Gastroenterol., 7.","DOI":"10.1186\/1471-230X-7-44"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3727\/105221618X15156018385515","article-title":"Bile Acid Metabolism in Liver Pathobiology","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s11427-023-2353-0","article-title":"Bile Acid Signaling in the Regulation of Whole Body Metabolic and Immunological Homeostasis","volume":"67","author":"Jia","year":"2024","journal-title":"Sci. China Life Sci."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Wang, Y., Nakajima, T., Gonzalez, F.J., and Tanaka, N. (2020). PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062061"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR Agonists for the Treatment of Primary Biliary Cholangitis: Old and New Tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"J. Transl. Autoimmun."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"da Rocha, G.H.O., M\u00fcller, C., Przybylski-Wartner, S., Schaller, H., Riemschneider, S., and Lehmann, J. (2024). AhR-Induced Anti-Inflammatory Effects on a Caco-2\/THP-1 Co-Culture Model of Intestinal Inflammation Are Mediated by PPAR\u03b3. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252313072"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Adamowicz, M., Kempinska-Podhorodecka, A., Abramczyk, J., Banales, J.M., Milkiewicz, P., and Milkiewicz, M. (2022). Suppression of Hepatic PPAR\u03b1 in Primary Biliary Cholangitis Is Modulated by miR-155. Cells, 11.","DOI":"10.3390\/cells11182880"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.2174\/09298673113209990136","article-title":"Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment","volume":"20","author":"Zardi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1745-7254.2006.00299.x","article-title":"PPAR Gamma Inhibits Growth of Rat Hepatic Stellate Cells and TGF Beta-Induced Connective Tissue Growth Factor Expression","volume":"27","author":"Sun","year":"2006","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.20104","article-title":"Disruption of Transforming Growth Factor Beta Signaling and Profibrotic Responses in Normal Skin Fibroblasts by Peroxisome Proliferator-Activated Receptor Gamma","volume":"50","author":"Ghosh","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"117303","DOI":"10.1016\/j.biopha.2024.117303","article-title":"PPAR\u03b2\/\u03b4 Attenuates Hepatic Fibrosis by Reducing SMAD3 Phosphorylation and P300 Levels via AMPK in Hepatic Stellate Cells","volume":"179","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jcmgh.2021.05.017","article-title":"(Pro)Renin Receptor Knockdown Attenuates Liver Fibrosis Through Inactivation of ERK\/TGF-\u03b21\/SMAD3 Pathway","volume":"12","author":"Hsieh","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-Liver Axis: Pathophysiological Concepts and Clinical Implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1186\/s40001-025-03073-6","article-title":"Nuclear Receptors in Metabolic, Inflammatory, and Oncologic Diseases: Mechanisms, Therapeutic Advances, and Future Directions","volume":"30","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"116344","DOI":"10.1016\/j.ejmech.2024.116344","article-title":"Design, Synthesis, and Biological Evaluation of Piperazine Derivatives as Pan-PPARs Agonists for the Treatment of Liver Fibrosis","volume":"269","author":"Sun","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"115165","DOI":"10.1016\/j.celrep.2024.115165","article-title":"The Adiponectin-PPAR\u03b3 Axis in Hepatic Stellate Cells Regulates Liver Fibrosis","volume":"44","author":"Zhao","year":"2025","journal-title":"Cell Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e13072","DOI":"10.1111\/cpr.13072","article-title":"EZH2-Mediated Inhibition of KLF14 Expression Promotes HSCs Activation and Liver Fibrosis by Downregulating PPAR\u03b3","volume":"54","author":"Du","year":"2021","journal-title":"Cell Prolif."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"175322","DOI":"10.1016\/j.ejphar.2022.175322","article-title":"Novel Dual PPAR\u03b1\/\u03b3 Agonists Protect against Liver Steatosis and Improve Insulin Sensitivity While Avoiding Side Effects","volume":"935","author":"Guru","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 Agonist Saroglitazar Improves Liver Histopathology and Biochemistry in Experimental NASH Models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential Effects of Selective- and Pan-PPAR Agonists on Experimental Steatohepatitis and Hepatic Macrophages\u2606","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2017.1312339","article-title":"PPAR-\u03b1 Agonists Are Still on the Rise: An Update on Clinical and Experimental Findings","volume":"26","author":"Ferri","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.1111\/j.1872-034X.2007.00232.x","article-title":"Fibrate for Treatment of Primary Biliary Cirrhosis","volume":"37","author":"Iwasaki","year":"2007","journal-title":"Hepatol. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJMe2313802","article-title":"PPAR Agonists in Primary Biliary Cholangitis","volume":"390","author":"Schnabl","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_112","first-page":"2757","article-title":"Combination Therapy of Fenofibrate and Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis Who Respond Incompletely to UDCA Monotherapy: A Meta-Analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate Is Effective Adjunctive Therapy in the Treatment of Primary Biliary Cirrhosis: A Meta-Analysis","volume":"39","author":"Grigorian","year":"2015","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined Ursodeoxycholic Acid (UDCA) and Fenofibrate in Primary Biliary Cholangitis Patients with Incomplete UDCA Response May Improve Outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and Cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of Bezafibrate with Transplant-Free Survival in Patients with Primary Biliary Cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients with Primary Biliary Cholangitis","volume":"70","author":"Honda","year":"2019","journal-title":"Hepatology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients with Primary Biliary Cirrhosis and Dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The Efficacy of Ursodeoxycholic Acid and Bezafibrate Combination Therapy for Primary Biliary Cirrhosis: A Prospective, Multicenter Study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol. Res."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"(2017). European Association for the Study of the Liver EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients with Primary Biliary Cholangitis. J. Hepatol., 67, 145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC Primary Biliary Cholangitis Treatment and Management Guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of Pharmacological Therapies in Metabolic Dysfunction-Associated Steatohepatitis for Fibrosis Regression and MASH Resolution: Systematic Review and Network Meta-Analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Kamata, S., Honda, A., Ishikawa, R., Akahane, M., Fujita, A., Kaneko, C., Miyawaki, S., Habu, Y., Shiiyama, Y., and Uchii, K. (2023). Functional and Structural Insights into the Human PPAR\u03b1\/\u03b4\/\u03b3 Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor. Antioxidants, 12.","DOI":"10.3390\/antiox12081523"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a Selective PPAR-\u03b4 Agonist, in Patients with Primary Biliary Cholangitis with an Inadequate Response to Ursodeoxycholic Acid: A Double-Blind, Randomised, Placebo-Controlled, Phase 2, Proof-of-Concept Study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"102056","DOI":"10.1016\/j.jbc.2022.102056","article-title":"Selective PPAR\u03b4 Agonist Seladelpar Suppresses Bile Acid Synthesis by Reducing Hepatocyte CYP7A1 via the Fibroblast Growth Factor 21 Signaling Pathway","volume":"298","author":"Kouno","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","article-title":"A Phase II, Randomized, Open-Label, 52-Week Study of Seladelpar in Patients with Primary Biliary Cholangitis","volume":"77","author":"Bowlus","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar Efficacy and Safety at 3 Months in Patients with Primary Biliary Cholangitis: ENHANCE, a Phase 3, Randomized, Placebo-Controlled Study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.14309\/ajg.0000000000003603","article-title":"Long-Term Efficacy and Safety of Selective PPAR\u03b4 Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results","volume":"121","author":"Levy","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40261-013-0128-3","article-title":"Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPAR\u03b1 Agonist with Moderate PPAR\u03b3 Agonist Activity in Healthy Human Subjects","volume":"33","author":"Jani","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/13543784.2020.1839888","article-title":"The Nonalcoholic Steatohepatitis (NASH) Drug Development Graveyard: Established Hurdles and Planning for Future Success","volume":"29","author":"Drenth","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MPG.0000000000003796","article-title":"An Open Label, Randomized, Multicenter Study of Elafibranor in Children with Nonalcoholic Steatohepatitis","volume":"77","author":"Goyal","year":"2023","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A Randomized Placebo-Controlled Trial of Elafibranor in Patients with Primary Biliary Cholangitis and Incomplete Response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-024-02075-8","article-title":"Elafibranor: First Approval","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic Acid-a New Therapy in PBC and NASH","volume":"133","author":"Chapman","year":"2020","journal-title":"Br. Med. Bull."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis from a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","article-title":"COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis with Placebo and External Controls","volume":"120","author":"Kowdley","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/HEP.0000000000000864","article-title":"Primary Biliary Cholangitis Drug Evaluation and Regulatory Approval: Where Do We Go from Here?","volume":"80","author":"Jones","year":"2024","journal-title":"Hepatology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/MS9.0000000000002868","article-title":"Latest FDA Approved Drug Elafibranor (Iqirvo): A Novel Prospect for Treatment of Primary Biliary Cholangitis","volume":"87","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jhep.2025.04.025","article-title":"Safety and Efficacy of Elafibranor in Primary Sclerosing Cholangitis: The ELMWOOD Phase II Randomized-Controlled Trial","volume":"84","author":"Levy","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12072-015-9613-5","article-title":"New Cellular and Molecular Targets for the Treatment of Portal Hypertension","volume":"9","author":"Bosch","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejmech.2018.09.071","article-title":"Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPAR\u03b3 and PPAR\u03b4","volume":"159","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/157339905774574365","article-title":"Novel Approach to Treat Insulin Resistance, Type 2 Diabetes, and the Metabolic Syndrome: Simultaneous Activation of PPARalpha, PPARgamma, and PPARdelta","volume":"1","author":"Evans","year":"2005","journal-title":"Curr. Diabetes Rev."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR Agonist Lanifibranor Improves Portal Hypertension and Hepatic Fibrosis in Experimental Advanced Chronic Liver Disease","volume":"74","author":"Robert","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR Agonist Lanifibranor Improves Insulin Resistance and Hepatic Steatosis in Patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The Pan-PPAR Agonist Lanifibranor Improves Cardiometabolic Health in Patients with Metabolic Dysfunction-Associated Steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mrc.4412","article-title":"Identification of By-Products in Support of Process Development of Muraglitazar","volume":"55","author":"Pathirana","year":"2017","journal-title":"Magn. Reson. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s11739-026-04326-w","article-title":"Efficacy of Tirzepatide, Lanifibranor, and Resmetirom in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of High-Quality Randomized Controlled Trials","volume":"21","author":"Zhao","year":"2026","journal-title":"Intern. Emerg. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e70003","DOI":"10.1111\/eci.70003","article-title":"Pharmacological Treatment Options for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review","volume":"55","author":"Konings","year":"2025","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Palomer, X., Wang, J.-R., Tang, X., Wu, S., Rodr\u00edguez-Calvo, R., Wahli, W., and V\u00e1zquez-Carrera, M. (2026). Peroxisome Proliferator-Activated Receptor \u03b2\/\u03b4: A Link Between Metabolism, Inflammation, and Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Cells, 15.","DOI":"10.3390\/cells15050464"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"goae029","DOI":"10.1093\/gastro\/goae029","article-title":"Advancements in Pharmacological Treatment of NAFLD\/MASLD: A Focus on Metabolic and Liver-Targeted Interventions","volume":"12","author":"Ciardullo","year":"2024","journal-title":"Gastroenterol. Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic Review with Network Meta-Analysis: Comparative Efficacy of Pharmacologic Therapies for Fibrosis Improvement and Resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/HEP.0000000000001028","article-title":"Comparative Efficacy of Pharmacologic Therapies for MASH in Reducing Liver Fat Content: Systematic Review and Network Meta-Analysis","volume":"83","author":"Koh","year":"2026","journal-title":"Hepatology"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Gallo, G., Nalli, G., Baratta, F., Desideri, G., and Savoia, C. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26168081"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40261-022-01219-6","article-title":"Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"42","author":"Durga","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e70558","DOI":"10.1111\/liv.70558","article-title":"Saroglitazar 4\u2009Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results from Phase 4 Study","volume":"46","author":"Sanyal","year":"2026","journal-title":"Liver Int."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and Safety of Saroglitazar in Real-World Patients of Non-Alcoholic Fatty Liver Disease with or without Diabetes Including Compensated Cirrhosis: A Tertiary Care Center Experience","volume":"7","author":"Chaudhuri","year":"2023","journal-title":"JGH Open"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jceh.2021.03.012","article-title":"Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients with Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study","volume":"12","author":"Rajesh","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e70144","DOI":"10.1002\/edm2.70144","article-title":"Effectiveness of Saroglitazar in MASLD Patients: A Prospective, Real-World Assessment of Liver and Metabolic Health","volume":"9","author":"Gupta","year":"2026","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_167","first-page":"e76716","article-title":"Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options","volume":"17","author":"Koullias","year":"2025","journal-title":"Cureus"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1111\/dom.16348","article-title":"Comparative Efficacy and Safety of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease over 24\u2009Weeks in Reducing Liver Steatosis and Fibrosis: A Network Meta-Analysis","volume":"27","author":"Zhong","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/hbsn-21-579","article-title":"Pan-Peroxisome Proliferator-Activated Receptor Agonist Lanifibranor as a Dominant Candidate Pharmacological Therapy for Nonalcoholic Fatty Liver Disease","volume":"11","author":"Yoneda","year":"2022","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Saeedian, B., Babajani, N., Bagheri, T., Shirmard, F.O., and Pourfaraji, S.M. (2025). Efficacy and Safety of PPAR Agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-03821-2"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"17562848251370111","DOI":"10.1177\/17562848251370111","article-title":"Efficacy and Safety of PPAR Agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis","volume":"18","author":"Liao","year":"2025","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/apt.17755","article-title":"Open-Label, Clinical Trial Extension: Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis","volume":"59","author":"Mayo","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-Concept Study to Evaluate the Safety and Efficacy of Saroglitazar in Patients with Primary Biliary Cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Kamata, S., Honda, A., and Ishii, I. (2023). Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease. Biomolecules, 13.","DOI":"10.3390\/biom13081264"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e0612","DOI":"10.1097\/HC9.0000000000000612","article-title":"PPAR Agonists for the Treatment of Cholestatic Liver Diseases: Over a Decade of Clinical Progress","volume":"9","author":"Hayes","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e70271","DOI":"10.1111\/liv.70271","article-title":"Safety Choice Drivers of the Coming Treatment Options for Non-Cirrhotic Metabolic Steatohepatitis","volume":"45","author":"Mangia","year":"2025","journal-title":"Liver Int."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"91319","DOI":"10.5662\/wjm.v14.i2.91319","article-title":"Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Emerging Evidence of Benefit of Peroxisome Proliferator-Activated Receptors Agonists and Incretin-Based Therapies","volume":"14","author":"Pramanik","year":"2024","journal-title":"World J. Methodol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e70196","DOI":"10.1002\/jgh3.70196","article-title":"Peroxisome Proliferator-Activated Receptor (PPAR) Agonists for Patients with Primary Biliary Cholangitis with Inadequate Response to Ursodeoxycholic Acid (UDCA): A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Zaidi","year":"2025","journal-title":"JGH Open"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1080\/14656566.2024.2406268","article-title":"Revisiting PPAR Agonists: Novel Perspectives in the Treatment of Primary Biliary Cholangitis","volume":"25","author":"Chen","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Romeo, M., Di Nardo, F., Basile, C., Napolitano, C., Vaia, P., Martinelli, G., Gregorio, A.D., Puorto, L.D., Indipendente, M., and Dallio, M. (2025). The Personalized Management of Primary Biliary Cholangitis in the Era of Precision Medicine: Current Challenges and Future Perspectives. J. Pers. Med., 15.","DOI":"10.3390\/jpm15120597"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.molmed.2020.04.006","article-title":"Multitissue Multiomics Systems Biology to Dissect Complex Diseases","volume":"26","author":"Yang","year":"2020","journal-title":"Trends Mol. Med."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Kouser, S., Sharma, S.V., Bhanu, A., Kukkupuni, S.K., and Vishnuprasad, C.N. (2026). A Transdisciplinary Framework for Managing Metabolic Dysfunction Associated Steatotic Liver Disease. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1767844"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Bourganou, M.V., Chondrogianni, M.E., Kyrou, I., Flessa, C.-M., Chatzigeorgiou, A., Oikonomou, E., Lambadiari, V., Randeva, H.S., and Kassi, E. (2025). Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202501.0541.v1"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Gravina, A.G., Romeo, M., Pellegrino, R., Tuccillo, C., Federico, A., and Loguercio, C. (2022). Just Drink a Glass of Water? Effects of Bicarbonate-Sulfate-Calcium-Magnesium Water on the Gut-Liver Axis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.869446"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1186\/s12967-025-07253-0","article-title":"A Novel Palmitoylation-Based Molecular Signature Reveals COX6A1 as a Key Regulator in Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"23","author":"Yu","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Romeo, M., Dallio, M., Di Nardo, F., Napolitano, C., Vaia, P., Martinelli, G., Federico, P., Olivieri, S., Iodice, P., and Federico, A. (2025). The Role of the Gut-Biliary-Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications. J. Pers. Med., 15.","DOI":"10.3390\/jpm15040124"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41392-025-02500-8","article-title":"The Aryl Hydrocarbon Receptor: Structure, Signaling, Physiology and Pathology","volume":"11","author":"Coumoul","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"116339","DOI":"10.1016\/j.taap.2022.116339","article-title":"Crosstalk between the Aryl Hydrocarbon Receptor (AhR) and the Peroxisome Proliferator-Activated Receptor Gamma (PPAR\u03b3) as a Key Factor in the Metabolism of Silver Nanoparticles in Neuroblastoma (SH-SY5Y) Cells in Vitro","volume":"458","author":"Matuszewska","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e70948","DOI":"10.1111\/jcmm.70948","article-title":"PPARevolution. First PPAR\u03b4 Agonist and a Dual PPAR\u03b1\/PPAR\u03b4 Activator Approved for the Treatment of Primary Biliary Cholangitis","volume":"29","author":"Popescu","year":"2025","journal-title":"J. Cell. Mol. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"8870546","DOI":"10.1155\/ijh\/8870546","article-title":"Randomized Controlled Trial Evidence on Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis","volume":"2025","author":"Dar","year":"2025","journal-title":"Int. J. Hepatol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e70630","DOI":"10.1111\/liv.70630","article-title":"Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE","volume":"46","author":"Levy","year":"2026","journal-title":"Liver Int."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/apt.70598","article-title":"Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis","volume":"63","author":"Schattenberg","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e70276","DOI":"10.1111\/liv.70276","article-title":"Assessment of PBC Pruritus from the ITCH-E Study: Quality of Life, Productivity, and Treatment Experiences","volume":"45","author":"Levy","year":"2025","journal-title":"Liver Int."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar Treatment Reduces IL-31 and Pruritus in Patients with Primary Biliary Cholangitis","volume":"80","author":"Kremer","year":"2024","journal-title":"Hepatology"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e70118","DOI":"10.1111\/liv.70118","article-title":"Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study","volume":"45","author":"Alvaro","year":"2025","journal-title":"Liver Int."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Fiorucci, S., Urbani, G., Di Giorgio, C., Biagioli, M., and Distrutti, E. (2024). Current Landscape and Evolving Therapies for Primary Biliary Cholangitis. Cells, 13.","DOI":"10.3390\/cells13181580"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Jamal, F., Elshaer, A., Alatout, M.H., Odeh, N.B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., and Worden, A.R. (2025). Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor. Biomedicines, 13.","DOI":"10.3390\/biomedicines13102335"},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Ruiu, A., Calabrese, M.P., Meschisi, P., Plebani, R., Buzias, M., Lleo, A., and Ronca, V. (2026). From Unmet Needs to New Possibilities: PPAR-Targeted Therapies in the Journey of People Living with Primary Biliary Cholangitis. Eur. J. Intern. Med., 106883.","DOI":"10.1016\/j.ejim.2026.106883"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/HEP.0000000000001511","article-title":"PPARidgm Shifts in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"83","author":"Abushamat","year":"2026","journal-title":"Hepatology"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.tem.2025.03.006","article-title":"Advancing Precision Medicine in Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"36","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Ma, J., Ma, Y., Wan, X., Li, J., Zhang, Y., Liu, J., and Gao, Y. (2025). Metabolic and Genetic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease: An Integrative Perspective from Molecular Pathways to Clinical Challenges. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1639064"},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Karapanagiotidi, F., Boutari, C., and Sinakos, E. (2026). Genetic Predisposition to MASLD: Potential for Therapeutic Management. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27041933"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Weiskirchen, R., and Lonardo, A. (2025). Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199594"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Li, Z., Chu, H., and Yang, L. (2025). White Adipose Tissue Browning and Peroxisome Proliferator Activated Receptors in MASLD. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1667037"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Dinerman, S., and Shu, Y. (2025). Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials. Int. J. Transl. Med., 5.","DOI":"10.3390\/ijtm5010007"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"110827","DOI":"10.4292\/wjgpt.v16.i4.110827","article-title":"Quick Glance at \u201cmetabolic Dysfunction Associated Steatotic Liver Disease\u201d Therapeutics: Targets, Trials, and Trends","volume":"16","author":"Zacharia","year":"2025","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4103\/ijem.ijem_528_24","article-title":"Fenofibrate in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis","volume":"29","author":"Kumar","year":"2025","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.3748\/wjg.v30.i35.3965","article-title":"Peroxisome Proliferator-Activated Receptor Agonists: A New Hope towards the Management of Alcoholic Liver Disease","volume":"30","author":"Durairajan","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Qiu, Y., Laguna, J.C., Alegret, M., and Vil\u00e0, L. (2026). A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation. Nutrients, 18.","DOI":"10.3390\/nu18040679"},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Fan, A., Zhang, J., and Ye, Q. (2025). Osteosarcopenia in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanisms to Management. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1706068"},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Ferdous, S.-E., and Ferrell, J.M. (2024). Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168731"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"113149","DOI":"10.4239\/wjd.v17.i2.113149","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes: Pathophysiology, Diagnosis, and Emerging Therapeutic Strategies","volume":"17","author":"Suresh","year":"2026","journal-title":"World J. Diabetes"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Theys, C., Vanderhaeghen, T., Van Dijck, E., Peleman, C., Scheepers, A., Ibrahim, J., Mateiu, L., Timmermans, S., Vanden Berghe, T., and Francque, S.M. (2023). Loss of PPAR\u03b1 Function Promotes Epigenetic Dysregulation of Lipid Homeostasis Driving Ferroptosis and Pyroptosis Lipotoxicity in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD). Front. Mol. Med., 3.","DOI":"10.3389\/fmmed.2023.1283170"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Zaiou, M. (2023). Peroxisome Proliferator-Activated Receptor-\u03b3 as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease. Cells, 12.","DOI":"10.3390\/cells12081205"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/HEP.0000000000000182","article-title":"Hepatic Fibrosis: Targeting Peroxisome Proliferator-Activated Receptor Alpha from Mechanism to Medicines","volume":"78","author":"Gong","year":"2023","journal-title":"Hepatology"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00109-025-02599-w","article-title":"Involvement of Ferroptosis in Metabolic Dysfunction-Associated Steatohepatitis-Related Liver Diseases","volume":"103","author":"Liu","year":"2025","journal-title":"J. Mol. Med."},{"key":"ref_217","first-page":"rs","article-title":"Integrated Spheroid-to-Population Framework for Evaluating PFHpA-Associated Metabolic Dysfunction and Steatotic Liver Disease","volume":"rs. 3","author":"Baumert","year":"2025","journal-title":"Res. Sq."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"111323","DOI":"10.3748\/wjg.v31.i39.111323","article-title":"Multi-Model Applications and Cutting-Edge Advancements of Artificial Intelligence in Hepatology in the Era of Precision Medicine","volume":"31","author":"Zheng","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Kong, Y., Chen, H., Chen, Y., and Wang, C. (2026). The Application of Artificial Intelligence in the Intersection of Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1788249"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/jcp-2025-210311","article-title":"AI Portal Tract Detection and Characterisation for a Regional Analysis of Steatosis and Inflammation in MASLD, MASH and AIH","volume":"79","author":"Windell","year":"2026","journal-title":"J. Clin. Pathol."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Martinou, E., Pericleous, M., Stefanova, I., Kaur, V., and Angelidi, A.M. (2022). Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics, 12.","DOI":"10.3390\/diagnostics12020407"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.3350\/cmh.2022.0348","article-title":"Noninvasive Serum Biomarkers for Liver Fibrosis in NAFLD: Current and Future","volume":"29","author":"Reinson","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gutjnl-2025-337431","article-title":"Combination Therapies for Metabolic Dysfunction-Associated Steatohepatitis: Challenges and Opportunities","volume":"75","author":"Zhou","year":"2026","journal-title":"Gut"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"e186425","DOI":"10.1172\/JCI186425","article-title":"Therapeutic Horizons in Metabolic Dysfunction-Associated Steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"101708","DOI":"10.1016\/j.jhepr.2025.101708","article-title":"Efficacy and Safety of GLP-1 Receptor Agonists in MASH with Fibrosis: A Systematic Review and Meta-Analysis","volume":"8","author":"Abreu","year":"2026","journal-title":"JHEP Rep."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Tornea, D.A., Goldis, C., Isaic, A., Motofelea, A.C., Sima, A.C., Ciocarlie, T., Crintea, A., Diaconescu, R.G., Motofelea, N., and Goldis, A. (2026). The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18010086"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis: November 2025 Updates to AASLD Practice Guidance","volume":"83","author":"Bansal","year":"2026","journal-title":"Hepatology"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41575-026-01187-8","article-title":"Therapeutic Targets for Metabolic Dysfunction-Associated Steatohepatitis: A Personalized Approach to Disease Management","volume":"23","author":"Rinella","year":"2026","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and Efficacy of Combination Therapy with Semaglutide, Cilofexor and Firsocostat in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Open-Label Phase II Trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.livres.2025.10.004","article-title":"Resmetirom and beyond: A New Era in MASLD Therapeutics","volume":"9","author":"Simmons","year":"2025","journal-title":"Liver Res."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Lu, X., Wang, S., Du, Y., Xie, B., Chen, Q., Lin, J., Chen, B., and Cui, K. (2025). KYLO-0603, a Novel Liver-Targeting, Thyroid Hormone Receptor-\u03b2 Agonist for the Inhibition of MASH Progression. PLoS ONE, 20.","DOI":"10.1101\/2025.02.09.637336"},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Tang, G., Zhang, J., Zhang, L., Xia, L., Tang, X., Chen, R., and Zhou, R. (2024). Efficacy and Safety of Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Primary Biliary Cholangitis: A Meta-Analysis of Randomized Controlled Trials. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1432814"},{"key":"ref_234","first-page":"e99044","article-title":"Role of Saroglitazar in Improving Transient Elastography Parameters in Significant and Advanced Metabolic Dysfunction-Associated Steatohepatitis","volume":"17","author":"Kak","year":"2025","journal-title":"Cureus"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"111409","DOI":"10.3748\/wjg.v31.i40.111409","article-title":"Microbiome and Gut-Liver Interactions: From Mechanisms to Therapies","volume":"31","author":"Anis","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065-Deuterium-Stabilized (R)-Pioglitazone in Patients with NASH: A Phase II Randomized Placebo-Controlled Trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"100065","DOI":"10.1016\/j.molpha.2025.100065","article-title":"The Peroxisome Proliferator-Activated Receptor \u03b1\/\u03b2\/\u03b3 Agonist NCPC-626 from Microbial Metabolites Alleviates Metabolic Dysfunction-Associated Steatohepatitis in Mice","volume":"107","author":"Yu","year":"2025","journal-title":"Mol. Pharmacol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"119432","DOI":"10.1016\/j.biopha.2026.119432","article-title":"Combination Therapy with Clinically Approved PPAR\u03b1\/\u03b4\/\u03b3 Subtype-Selective Agonists Pemafibrate, Seladelpar, and Pioglitazone in a 4-Week Diet-Induced Early-Stage MASLD Mouse Model","volume":"199","author":"Honda","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/HEP.0000000000001475","article-title":"Chiglitazar in MASLD with Hypertriglyceridemia and Insulin Resistance: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study","volume":"83","author":"Sun","year":"2026","journal-title":"Hepatology"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40801-024-00426-1","article-title":"Safety of Combined Statin and Fibrate Therapy: Risks of Liver Injury and Acute Kidney Injury in a Cohort Study from the Shizuoka Kokuho Database","volume":"11","author":"Sobukawa","year":"2024","journal-title":"Drugs Real. World Outcomes"},{"key":"ref_241","first-page":"3","article-title":"Elafibranor Long-Term Efficacy and Safety and Impact on Fatigue in Primary Biliary Cholangitis: Interim Results from the Open-Label Extension of the ELATIVE Trial Up to 3 Years","volume":"20","author":"Gish","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_242","unstructured":"(2024). One-Year Treatment with Elafibranor in the Phase 3 ELATIVE Trial Improves GLOBE and UK-PBC Prognostic Scores. Gastroenterol. Hepatol., 20, 9\u201310."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/HEP.0000000000000826","article-title":"Predictive Factors for Decompensating Events in Patients with Cirrhosis with Primary Biliary Cholangitis under Different Lines of Therapy","volume":"80","author":"Ampuero","year":"2024","journal-title":"Hepatology"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:52:44Z","timestamp":1784508764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":243,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cells15141292"],"URL":"https:\/\/doi.org\/10.3390\/cells15141292","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,19]]}}}